AC Immune Banner Image

AC Immune has reached its limit for free report views

Work for AC Immune? Upgrade Your Profile and unlock all your annual reports.

AC Immune

  • Ticker ACIU
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
AC Immune Logo Image
  • 51-200 Employees
  • Based in Lausanne, Switzerland
AC Immune is a clinical-stage Swiss-based biopharmaceutical company, listed on Nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms createMore antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer’s disease (AD). The Company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. The most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal IgG4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. Crenezumab is currently in two Phase 3 clinical studies for AD, under a global program conducted by the collaboration partner Genentech (a member of the Roche Group). Other collaborations include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences, Piramal Imaging and Essex Bio-Technology.
AC Immune

Most Recent Annual Report

AC Immune MOST RECENT 2019 Annual Report

Report Locked. AC Immune has reached its limit for free report views.

Older/Archived Annual Reports